
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc is developing a traditional antigen-based vaccine platform, which may be more favorably perceived in the current regulatory climate compared to mRNA-based alternatives. The company has demonstrated strong clinical results in its malaria and influenza vaccine programs, highlighting the versatility of its platform beyond its initial COVID-19 vaccine. Additionally, there are several potential upsides to revenue forecasts, including strategic partnerships, earlier-than-expected product approvals, and increased pricing or adoption rates for its marketed vaccines.
Bears say
Novavax Inc. is expected to experience a decline in total revenues in the short term due to significant payouts related to the Sanofi deal, raising concerns about immediate financial stability. The company's strategy to cut costs includes a reduction in research and development and selling, general, and administrative expenses from $1.2 billion in 2023 to $250 million by 2027, indicating potential challenges in maintaining operational effectiveness. This combination of reduced revenues and aggressive cost-cutting measures may adversely affect the company's ability to achieve sustainable growth and profitability in the near future.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares